High-Dose MEDI5752 Induces Clinical Benefit in NSCLC at the Cost of Significant Toxicity
MEDI5752 plus chemotherapy doubled the duration of response and extended survival compared with pembrolizumab in patients with treatment-naïve nonsquamous non–small cell lung cancer.
POU2F2 May Be Predictive of Survival Benefit With Maintenance Avelumab in Urothelial Carcinoma
September 11th 2022The absence of POU2F2, may be predictive of response to maintenance avelumab in patients with advanced or metastatic urothelial carcinoma, according to findings from an analysis peripheral blood samples taken in the JAVELIN Bladder 100 trial.
Rucaparib Maintenance Elicits PFS Benefit in Newly Diagnosed Ovarian Cancer
September 11th 2022First-line rucaparib maintenance therapy improved progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study.
Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer
September 11th 2022Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.
Addition of Enzalutamide to Abiraterone/Prednisolone Deemed Unnecessary in Metastatic HSPC
September 11th 2022Although the combination of androgen deprivation therapy, abiraterone acetate, and prednisolone showed a clinically meaningful 7-year improvement in overall survival, AAP plus enzalutamide is not recommended in patients with metastatic hormone-sensitive prostate cancer.
Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC
September 11th 2022The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.
Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCC
September 11th 2022The addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.
Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC
September 11th 2022Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.
Pembrolizumab Plus Abiraterone/Prednisone Shows Sustained Efficacy in Chemotherapy-Naïve mCRPC
September 10th 2022Pembrolizumab plus abiraterone acetate and prednisone demonstrated continued efficacy and tolerability in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Naporafenib Combinations Prove Effective in NRAS-Mutant Unresectable/Metastatic Melanoma
The investigational type II RAF inhibitor naporafenib exhibited favorable efficacy with a tolerable safety profile in combination with rineterkib, trametinib, or ribociclib in patients with previously treated, unresectable or metastatic melanoma.
Trastuzumab Deruxtecan Maintains Clinical Benefit in Metastatic Gastric/GEJ Cancer
September 10th 2022Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.
Amcenestrant did not significantly improve progression-free survival over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer, but it did provide a benefit that was numerically comparable, according to data from the phase 2 AMEERA-3 trial.
Second-line Cemiplimab Produces Long-Term OS Benefit in Recurrent/Metastatic Cervical Cancer
September 10th 2022Cemiplimab maintained an overall survival benefit vs chemotherapy as a second-line treatment for patients with recurrent or metastatic cervical cancer who received prior platinum-based chemotherapy.
ADP-A2M4CD8 Shows Promising Activity Across MAGE-A4+ Unresectable or Metastatic Tumor Types
September 10th 2022An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.
Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Exposure to Environmental Carcinogens May Increase Risk for EGFR+ NSCLC
September 10th 2022Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.
TILs Demonstrate Improved PFS Vs Ipilimumab in Unresectable Melanoma
A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.
Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC
First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.